文献速递临床试验与 GCP基础与转化研究

一氧化氮合酶抑制剂L-NMMA联合紫杉烷类治疗化疗耐药三阴性乳腺癌的1/2期临床试验

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
PubMed 文献 · Sci Transl Med · 2021-12-15

该1/2期试验评估L-NMMA联合紫杉烷类治疗化疗难治性局部晚期或转移性三阴性乳腺癌。24例可评估患者总体缓解率45.8%(11/24),局部晚期患者81.8%(9/11),转移性患者15.4%(2/13)。≥3级毒性21%,无不良事件归因于L-NMMA。

要点

  • L-NMMA联合紫杉烷类在局部晚期三阴性乳腺癌中缓解率81.8%(9/11)。
  • 转移性三阴性乳腺癌缓解率15.4%(2/13),总体缓解率45.8%(11/24)。
  • ≥3级毒性21%,无不良事件归因于L-NMMA。

核心结论

  • L-NMMA联合紫杉烷类值得在更大规模的乳腺癌临床研究中进一步研究。

研究设计与样本

  • 首次1/2期试验,评估L-NMMA联合紫杉烷类治疗化疗难治性局部晚期乳腺癌或转移性三阴性乳腺癌。
  • 共招募35例转移性三阴性乳腺癌患者:1期15例,2期24例(包括1期中4例推荐2期剂量患者)。

主要发现

  • 总体缓解率为45.8%(11/24):局部晚期乳腺癌患者为81.8%(9/11),转移性三阴性乳腺癌患者为15.4%(2/13)。
  • 局部晚期乳腺癌患者中3例手术时达到病理完全缓解(27.3%)。
  • ≥3级毒性发生率为21%,但无不良事件归因于L-NMMA。
  • CyTOF分析显示化疗无应答者M2巨噬细胞极化相关标志物表达更高,循环IL-6和IL-10浓度升高。
  • 化疗应答者血液中CD15+中性粒细胞增加,治疗结束时肿瘤活检中精氨酸酶(促肿瘤N2中性粒细胞标志物)降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The inducible nitric oxide signaling (iNOS) pathway is associated with poor prognosis in triple-negative breast cancer (TNBC). Prior studies using in vivo models showed that inhibition of the iNOS signaling pathway using the pan-NOS inhibitor NG-monomethyl-l-arginine (L-NMMA) reduced tumor growth and enhanced survival in patients with TNBC. Here, we report a first-in-class phase 1/2 trial of L-NMMA combined with taxane for treating patients with chemorefractory, locally advanced breast cancer (LABC) or metastatic TNBC. We also examined immune cell correlates of chemotherapy response. 35 patients with metastatic TNBC were recruited: 15 in the phase 1 trial and 24 in the phase 2 trial (including 4 recommended phase 2 dose patients from the phase 1 trial). The overall response rate was 45.8% (11 of 24): 81.8% (9 of 11) for patients with LABC and 15.4% (2 of 13) for patients with metastatic TNBC. Among the patients with LABC, three patients had a pathological complete response at surgery (27.3%). Grade ≥3 toxicity was noted in 21% of patients; however, no adverse events were attributed to L-NMMA. Immune cells analyzed by CyTOF indicated that chemotherapy nonresponders showed greater expression of markers associated with M2 macrophage polarization and increased concentrations of circulating IL-6 and IL-10 cytokines. In contrast, chemotherapy responders showed an increase in CD15+ neutrophils in blood, as well as a decrease in arginase (a marker of protumor N2 neutrophils) in tumor biopsies obtained at the end of treatment. L-NMMA combined with taxane warrants further investigation in larger clinical studies of patients with breast cancer.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Chung AW, Anand K, Anselme AC, et al. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021. PMID: 34910551. doi:10.1126/scitranslmed.abj5070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。